Wechselwirkungen · Sunlenca
Sunlenca 300 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 23
HOS-148340 · Präparat HOS-099874
Tenofovirk: AUC:↑ 47% Cmax:↑ 23% ERGOT DERIVATIVES Dihydroergotamine Interaction not studied. Caution is warranted when Ergotamine dihydroergotamine or ergotamine, Plasma concentrations of these is co-administered with Sunlenca. medicinal products may be increased when co-administered with lenacapavir. PHOSPHODIESTERASE-5 (PDE-5) INHIBITORS Sildenafil Interaction not studied. Use of PDE-5 inhibitors for Tadalafil pulmonary arterial hypertension: Vardenafil Plasma concentration of PDE-5 Co-administration with tadalafil is inhibitors may be increased when not recommended. co-administered with lenacapavir. Use of PDE-5 inhibitors for erectile dysfunction: Sildenafil: A starting dose of 25 mg is recommended. Vardenafil: No more than 5 mg in a 24-hour period. Tadalafil: • For use as needed: no more than 10 mg every 72 hours • For once daily use: dose not to exceed 2.5 mg
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tadalafil (HOS-086316) sildenafil (HOS-086162) ergotamine (HOS-086154) dihydroergotamine (HOS-086152) vardenafil (HOS-086163)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-02-26T15:19:00Z · SHA-256 5e82373c9638ee4d24450180684e7d233b6a19a1b3755e36a56d1822304f7bda · Passage 9874519b9d48c74498c5f2469c9b9db7bdbc05ab1fa39d1ab2a4ccfe12071249 · Zeichen 6306–8541 im Abschnitt